Rockwell Medical reports Q3 adjusted EPS 0c vs. 9c last year

Reports Q3 revenue $15.93M vs. $28.32M last year. The decrease in net sales was driven by the company’s largest customer transitioning to another supplier. “During the third quarter, we continued to right-size our organization to enhance operational efficiency and support long-term growth, while consistently meeting customer demand,” said Mark Strobeck, Ph.D., Rockwell Medical’s (RMTI) President and CEO. “Our proven track record of exceptional service, product quality, and manufacturing redundancy ensures uninterrupted supply of hemodialysis concentrates to dialysis providers treating patients with end-stage renal disease. Looking ahead, we are advancing targeted business development opportunities to expand our product portfolio and geographic footprint, while maintaining strict expense discipline and accelerating gross margin expansion on our path toward sustainable profitability.”